Search results
12 wrz 2023 · Summary of available prospective studies on investigated therapies for malignant ascites (malignant ascites (MA), overall survival (OS), progression free survival (PFS), cytoreductive surgery (CRS), heated intraperitoneal chemotherapy (HIPEC), computer tomography (CT)).
20 lis 2021 · The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.
27 kwi 2015 · The development of malignant ascites carries a poor prognosis, with the median survival reported anywhere between 1 and 4 months. 3,4 Patients with malignant ascites clinically present...
The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.
Malignant ascites of ovarian origin has a better prognosis even in the presence of ascites while patients with malignant ascites of GI origin or unknown origin have the worst outcome. Fifty-four per cent of our patients presented with ascites at the initial diagnosis of their cancer.
12 wrz 2023 · Malignant ascites (MA) is defined by the presence of tumor cells within the ascitic fluid. It does not only cause substantial morbidity, but is also associated with impaired survival.
Medical management Evidence for diuretics less clear in malignant ascites. Serum-ascites albumin gradient (SAAG) can be calculated from ascitic tap. SAAG >1.1g/dL most likely to benefit. Spironolactone is first line diuretic, starting at 100mg and titrated to 400mg every 3–4 days as required.
